Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
What it owns vs. what it owes Q2 FY2026, 30 June 2026
Liabilities are $29.6M more than assets: shareholders’ equity is negative. What is a balance sheet?
Owns
$4.3MLong-term assets
$5.5MOther short-term assets
$91.3MCash & short-term investments
Funded by
$130.7MOther liabilities
Debt is 0.0% of the total; liabilities are $29.6M more than assets.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
117.98 | 88.98 | 87.24 | 91.32 |
Receivables |
0.12 | 0.22 | 5.04 | 0.35 | |
Inventory |
3.86 | 3.74 | 3.38 | 3.38 | |
Total current assets |
133.42 | 99.07 | 101.36 | 96.83 | |
Long-Term Investments |
3.04 | 20.16 | 8.03 | 4.01 | |
Long-term assets (Other) |
0.56 | 0.36 | 0.25 | 0.24 | |
Total non-current assets |
3.59 | 20.52 | 8.27 | 4.25 | |
Total Assets |
137.01 | 119.59 | 109.63 | 101.08 | |
Accounts Payable |
5.09 | 3.75 | 5.09 | 7.51 | |
Accrued Expenses |
25.78 | 20.18 | 17.34 | 23.11 | |
Current Revenue (Deferred) |
5.10 | 5.31 | 5.68 | 5.42 | |
Total current liabilities |
35.97 | 29.24 | 28.11 | 36.04 | |
Non-current Revenue (Deferred) |
0.57 | 0.26 | 4.08 | 2.62 | |
Minority Interests |
21.48 | 21.48 | 21.48 | 21.48 | |
Non-current Liabilities (Other) |
82.98 | 85.62 | 86.73 | 70.56 | |
Total non-current liabilities |
105.04 | 107.36 | 112.29 | 94.66 | |
Total liabilities |
141.01 | 136.60 | 140.40 | 130.70 | |
Additional Paid In Capital |
1,676.00 | 1,677.18 | 1,679.30 | 1,680.27 | |
Common Stock (Net) |
1.01 | 1.01 | 0.04 | 0.04 | |
Retained Earnings |
(1,691.83) | (1,706.05) | (1,721.24) | (1,709.27) | |
Common Equity (Total) |
(3.99) | (17.01) | (30.77) | (29.62) | |
Shareholders Equity (Total) |
(3.99) | (17.00) | (30.77) | (29.62) | |
Shareholders Equity and Liabilities (Total) |
137.01 | 119.59 | 109.63 | 101.08 | |
Shares (Common) |
4.05 | 4.05 | 4.05 | 4.05 | |
Shareholders Equity (Tangible) |
(3.99) | (17.00) | (30.77) | (29.62) | |
Net Debt |
(117.97) | (88.98) | (87.24) | (91.32) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026